RT Journal Article
T1 Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
A1 Guardamagna, Mora
A1 Berciano-Guerrero, Miguel-Angel
A1 Villaescusa-González, Beatriz
A1 Perez-Ruiz, Elisabeth
A1 Oliver, Javier
A1 Lavado-Valenzuela, Rocío
A1 Rueda-Dominguez, Antonio
A1 Barragán, Isabel
A1 Queipo-Ortuño, María Isabel
K1 Gut microbiome
K1 Immune system
K1 Metastatic melanoma
AB Gut microbiome (GM) and its either pro-tumorigenic or anti-tumorigenic role is intriguing and constitutes an evolving landscape in translational oncology. It has been suggested that these microorganisms may be involved in carcinogenesis, cancer treatment response and resistance, as well as predisposition to adverse effects. In melanoma patients, one of the most immunogenic cancers, immune checkpoint inhibitors (ICI) and MAPK-targeted therapy-BRAF/MEK inhibitors-have revolutionized prognosis, and the study of the microbiome as a modulating factor is thus appealing. Although BRAF/MEK inhibitors constitute one of the main backbones of treatment in melanoma, little is known about their impact on GM and how this might correlate with immune re-induction. On the contrary, ICI and their relationship to GM has become an interesting field of research due to the already-known impact of immunotherapy in modulating the immune system. Immune reprogramming in the tumor microenvironment has been established as one of the main targets of microbiome, since it can induce immunosuppressive phenotypes, promote inflammatory responses or conduct anti-tumor responses. As a result, ongoing clinical trials are evaluating the role of fecal microbiota transplant (FMT), as well as the impact of using dietary supplements, antibiotics and probiotics in the prediction of response to therapy. In this review, we provide an overview of GM's link to cancer, its relationship with the immune system and how this may impact response to treatments in melanoma patients. We also discuss insights about novel therapeutic approaches including FMT, changes in diet and use of probiotics, prebiotics and symbiotics. Finally, we hypothesize on the possible pathways through which GM may impact anti-tumor efficacy in melanoma patients treated with targeted therapy, an appealing subject of which little is known.
PB MDPI
YR 2022
FD 2022-10-09
LK http://hdl.handle.net/10668/21203
UL http://hdl.handle.net/10668/21203
LA en
NO Boutriq S, González-González A, Plaza-Andrades I, Laborda-Illanes A, Sánchez-Alcoholado L, Peralta-Linero J, et al. Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer. J Pers Med. 2021 Jul 14;11(7):659
NO The work is funded by Novartis Farmaceutica S.A.-FIMABIS Contract (to M.-A.B.-G.). M.G. is completing a doctoral thesis at the University of Malaga, in the Medical School, Instituto de Salud Carlos III through the project PI18/01592 (to I.B.) (Co-funded by the European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”); Sistema Andaluz de Salud, through the projects SA 0263/2017, Nicolás Monarde (to I.B.), an PI-0121-2020 (to I.B. and E.P.-R.); Consejería de Transformación económica, Industria, Conocimiento y Universidades through the projects CV20-62050 and PY20_01326 (to I.B.); Spanish Group of Melanoma (Award to Best Research Project 2020) (to I.B.); Fundación Bancaria Unicaja through the project C19048 (to I.B.).
DS RISalud
RD Apr 4, 2025